Holen Sie sich die Stockscreener-App
4.65
19.23%
0.75
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
209.69%
0.9446
|
0.305 | 1.2674 | 0.0855 | 0.5811 |
Operating Expenses
|
35.68%
12.34
|
19.18 | 6.5903 | 6.5621 | 7.9831 |
| Interest Income/Expense |
1.94%
0.0764
|
0.0779 | 0.0697 | 0.0753 | 0.0924 |
| Benefits Costs and Expenses |
74.22%
5.9703
|
23.16 | 6.3697 | 6.9664 | 7.9349 |
| Costs And Expenses |
74.22%
5.9703
|
23.16 | 6.3697 | 6.9664 | 7.9349 |
| Operating Income/Loss |
39.65%
-11.39
|
-18.87 | -5.3229 | -6.4766 | -7.402 |
| Nonoperating Income/Loss |
259.80%
6.3649
|
-3.983 | 0.2206 | -0.4043 | 0.0482 |
| Income/Loss From Continuing Operations Before Tax |
78.01%
-5.0257
|
-22.86 | -5.1023 | -6.8809 | -7.3538 |
| Income/Loss From Continuing Operations After Tax |
78.01%
-5.0257
|
-22.86 | -5.1023 | -6.8809 | -7.3538 |
|
Net Income/Loss
|
78.01%
-5.0257
|
-22.86 | -5.1023 | -6.8809 | -7.3538 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
120.28%
9.2419
|
-45.56 | 52.41 | 50.42 | 50.40 |
| Diluted Average Shares |
120.28%
9.2419
|
-45.56 | 52.41 | - | 50.40 |
| Basic Earnings Per Share |
92.56%
-0.54
|
-7.26 | -0.10 | -0.14 | -0.15 |
| Diluted Earnings Per Share |
92.56%
-0.54
|
-7.26 | -0.10 | - | -0.15 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):